Some companies begin with an experienced founding team, a polished pitch deck and a well-trodden path to funding. CommonGround Labs, a company harnessing data to forecast violence and improve safety for operations and communities, began somewhere more fundamental:… Keep reading
The USC Stevens Center for Innovation is pleased to announce that Daikin Applied Americas (Daikin Applied) is now a licensee of a groundbreaking technology, invented at the university, that enables the reduction of indoor volatile organic compounds (VOCs) and supports… Keep reading
The University of Southern California (USC) is thrilled to announce that it has entered into an exclusive licensing agreement with the Ellison Medical Institute (EMI) for the rights to develop and commercialize a novel therapeutic drug for the treatment… Keep reading
USC has embarked on a collaboration with Autobahn Labs, an accelerator for early-stage drug discovery, to identify and advance cutting-edge scientific findings into new therapies – with a special focus on critical unmet medical needs. “Our collaboration with Autobahn Labs… Keep reading
Today is Veteran’s Day and according to the U.S. Department of Veterans Affairs (VA), over 6,000 Veterans die by suicide each year. This is approximately 17 lives lost every day. In response to this crisis, the VA… Keep reading
The new initiative brings together renowned experts at a researcher-founded biotechnology company with Keck School of Medicine (KSOM) experts to develop innovative solutions for heart failure, the global leading cause of death. Heart failure, which happens when the heart cannot… Keep reading
USC Stevens Center announces the execution of an exclusive, worldwide license between biotechnology company AcuraStem and biopharmaceutical company Takeda Pharmaceuticals. Keep reading
In honor of Brain Cancer Awareness Month, USC Stevens Center for Innovation is proud to announce that we have executed an exclusive global IP licensing agreement with NeOnc Technologies for an enhanced method of delivering novel pharma therapeutics to the brain. Keep reading